Skyclarys Access Battle in Ireland | Dublin News

A groundbreaking new drug for Friedreich’s ataxia, Skyclarys, has been approved in the US and Europe—but Ireland’s HSE is refusing to cover it, citing its steep €280K annual cost and uncertain clinical benefits. Though patients and advocates hail it as a life-changing therapy that could slow disease progression by up to 55%, the HSE’s drug group acknowledged its potential while rejecting reimbursement due to cost-effectiveness concerns. The decision has sparked legal action, as one patient secured High Court permission to challenge the delay—while a final HSE ruling looms in just two weeks. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/e839c2209946c458